Skip to main content

Table 4 Variables associated with endocrine therapy (ET) continuation for at least 12 months after initiation, stratified by race

From: Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer

 

aOR (95% CI)a

Independent variables

White

(n = 248)

Blackb

(n = 157)

Black/Other

(n = 162)

Age, years

0.96 (0.92-1.01)

0.98 (0.92-1.04)

0.98 (0.92-1.04)

Insurance status

 Private

Ref

Ref

Ref

 Public only or otherc

5.87 (0.36-94.67)

0.54 (0.18-1.57)

0.54 (0.19-1.58)

Chemotherapy

 No

Ref

Ref

Ref

 Yes

1.16 (0.39-3.46)

1.58 (0.54-4.58)

1.58 (0.54-4.57)

Radiation Therapy

 No

Ref

Ref

Ref

 Yes

1.62 (0.66-3.99)

1.12 (0.35-3.55)

1.16 (0.37-3.68)

Diabetes

 No

Ref

Ref

Ref

 Yes

0.49 (0.13-1.87)

1.23 (0.39-3.87)

1.19 (0.38-3.74)

Obesity

 No (BMI < 30 kg/m2)

Ref

Ref

Ref

 Yes (BMI ≥ 30 kg/m2)

1.20 (0.45-3.19)

0.85 (0.32-2.26)

0.83 (0.31-2.19)

Elevated depressed mood

 No (CESD < 16)

Ref

Ref

Ref

 Yes (CESD ≥16)

0.24 (0.07-0.78)*

0.96 (0.28-3.27)

0.94 (0.28-3.23)

 Menopausal-symptom severity

0.66 (0.41-1.07)

0.72 (0.39-1.32)

0.70 (0.38-1.30)

 Change in menopausal-symptom severity mean scoresd

0.77 (0.42-1.43)

1.42 (0.74-2.73)

1.40 (0.73-2.69)

  1. BMI body mass index, aOR adjusted odds ratio, CI confidence interval, CESD Center for Epidemiologic Studies Depression scale
  2. a Using diabetes, obesity, elevated depressed mood, and menopausal symptom data from the interview when ET initiation was first reported
  3. b Five patients (two Asian Indian/Pakistani, one Asian/Pacific Islander, and two unspecified because they did not respond to the question about race) were excluded from this sensitivity analysis stratified by race to compare the associations between ET continuation and variables of interest within each racial group
  4. c Other insurance status includes no insurance or self-pay
  5. d Change in menopausal-symptom severity mean scores from patient’s first reported use of ET to 12-18 month follow-up of ET continuation among patients who had used ET within 12 months of definitive surgery
  6. * P < 0.05